Atezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2024-01-01 DOI:10.2174/1574886318666230824155341

Aysu Sinem Koc, Orcun Can, Senol Kobak

{"title":"Atezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Report.","authors":"Aysu Sinem Koc, Orcun Can, Senol Kobak","doi":"10.2174/1574886318666230824155341","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer is one of the most common and mortal cancers worldwide. According to pathological and clinical groups, treatments vary, and a tailored approach is considered. Adjuvant therapies, such as chemotherapy, radiation, and immune checkpoint inhibitors (ICI), are recommended by recent guidelines for patients with locally advanced cancer.Objective: This study aimed to report the case of a patient with stage 2B squamous cell lung carcinoma who was managed for pulmonary toxicity after receiving adjuvant chemotherapy and atezolizumab treatment.Case report: A 66-year-old male patient received chemotherapy and immunotherapy after surgery for squamous cell lung cancer. A diagnosis of atezolizumab-associated pneumonitis was made using laboratory tests and imaging due to the patient's worsening dyspnea after treatment. Due to the patient's rapid progression, pulse steroid and MMF therapy were administered concurrently. When Klebsiella pneumoniae growth was detected in the sputum culture during the follow-up, IVIg was used to supplement the medication. The patient showed significant clinical and radiological improvement.Conclusion: In this study, we present an atezolizumab-induced pneumonitis case of a squamous cell lung cancer patient. It may be life-saving not to avoid aggressive treatment approaches by combining the steps of guideline recommendations in patients with rapidly progressive pneumonitis.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"469-473"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574886318666230824155341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lung cancer is one of the most common and mortal cancers worldwide. According to pathological and clinical groups, treatments vary, and a tailored approach is considered. Adjuvant therapies, such as chemotherapy, radiation, and immune checkpoint inhibitors (ICI), are recommended by recent guidelines for patients with locally advanced cancer.

Objective: This study aimed to report the case of a patient with stage 2B squamous cell lung carcinoma who was managed for pulmonary toxicity after receiving adjuvant chemotherapy and atezolizumab treatment.

Case report: A 66-year-old male patient received chemotherapy and immunotherapy after surgery for squamous cell lung cancer. A diagnosis of atezolizumab-associated pneumonitis was made using laboratory tests and imaging due to the patient's worsening dyspnea after treatment. Due to the patient's rapid progression, pulse steroid and MMF therapy were administered concurrently. When Klebsiella pneumoniae growth was detected in the sputum culture during the follow-up, IVIg was used to supplement the medication. The patient showed significant clinical and radiological improvement.

Conclusion: In this study, we present an atezolizumab-induced pneumonitis case of a squamous cell lung cancer patient. It may be life-saving not to avoid aggressive treatment approaches by combining the steps of guideline recommendations in patients with rapidly progressive pneumonitis.

查看原文本刊更多论文

阿特珠单抗肺部毒性：生命边缘联合治疗的重要性，病例报告。

背景：肺癌是全球最常见、最致命的癌症之一。根据病理和临床分组的不同，治疗方法也各不相同，因此需要考虑采取量身定制的方法。化疗、放疗和免疫检查点抑制剂（ICI）等辅助疗法被近期指南推荐用于局部晚期癌症患者：本研究旨在报告一例2B期鳞状细胞肺癌患者在接受辅助化疗和atezolizumab治疗后出现肺毒性的病例：病例报告：一名66岁的男性患者在鳞状细胞肺癌手术后接受了化疗和免疫治疗。由于患者在治疗后呼吸困难加重，通过实验室检查和影像学检查，诊断为阿特珠单抗相关性肺炎。由于病情发展迅速，患者同时接受了脉冲类固醇和 MMF 治疗。在随访期间，当痰培养中发现肺炎克雷伯菌生长时，患者使用了IVIg作为辅助药物。患者的临床和影像学症状均有明显改善：本研究介绍了一例鳞状细胞肺癌患者因阿特珠单抗引发的肺炎。对于急进性肺炎患者，结合指南建议的步骤，避免采取激进的治疗方法，可能会挽救患者的生命。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.